Estrella Immunopharma doses first patient in STARLIGHT-1 trial expansion for EB103 in relapsed B-cell NHL
ESLA•Early results and trial objective
Early results were already presented from the dose-escalation phase, showing responses that remained durable at a six-month assessment in evaluable patients without CNS involvement.
The expansion cohort aims to confirm safety and efficacy at the recommended Phase II dose to guide the pivotal-trial strategy.
First patient dosed in STARLIGHT-1 dose-expansion phase
Estrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 Phase I/II trial of EB103 in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
